CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-09-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −25,000 | $18.00 | $450K | 330,815 |
| 2018-09-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −20,000 | $21.01 | $420K | 310,815 |
| 2018-09-06 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −25,000 | 263,000 | ||
| 2018-09-06 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −20,000 | 243,000 | ||
| 2018-09-04 | Anzalone Christopher Richard Chief Executive Officer | Sale | −64,834 | $14.45 | $937K | 1,803,955 |
| 2018-08-31 | Anzalone Christopher Richard Chief Executive Officer | Sale | −100,000 | $14.45 | $1.4M | 1,868,789 |
| 2018-06-19 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise | +20,000 | $2.01 | $40K | 330,815 |
| 2018-06-19 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −20,000 | $14.01 | $280K | 310,815 |
| 2018-06-19 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −20,000 | 288,000 | ||
| 2018-05-31 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise | +12,600 | $2.01 | $25K | 323,415 |
| 2018-05-31 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −12,600 | $11.00 | $139K | 310,815 |
| 2018-05-31 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −12,600 | 308,000 | ||
| 2018-05-30 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise | +1,400 | $2.01 | $3K | 312,215 |
| 2018-05-30 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −1,400 | $11.00 | $15K | 310,815 |
| 2018-05-30 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −1,400 | 320,600 | ||
| 2018-04-24 | GIVEN DOUGLAS B Director | Sale | −25,000 | $6.63 | $166K | 155,000 |
| 2018-03-27 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise | +20,000 | $2.01 | $40K | 330,815 |
| 2018-03-27 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −20,000 | $8.00 | $160K | 310,815 |
| 2018-03-27 | Myszkowski Kenneth Allen Chief Financial Officer | Option exercise · Stock Option (right to buy) | −20,000 | 322,000 | ||
| 2018-03-16 | Anzalone Christopher Richard Chief Executive Officer | Sale | −26,000 | $7.40 | $192K | 1,968,789 |
Page 34 of 38 · 752 trades